Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1999 1
2003 1
2006 5
2007 3
2008 3
2009 6
2010 8
2011 6
2012 9
2013 8
2014 6
2015 4
2016 5
2017 3
2018 2
2019 1
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

67 results
Results by year
Filters applied: . Clear all
Page 1
PharmGKB summary: sorafenib pathways.
Gong L, Giacomini MM, Giacomini C, Maitland ML, Altman RB, Klein TE. Gong L, et al. Among authors: maitland ml. Pharmacogenet Genomics. 2017 Jun;27(6):240-246. doi: 10.1097/FPC.0000000000000279. Pharmacogenet Genomics. 2017. PMID: 28362716 Free PMC article. Review. No abstract available.
Cancer Clinical Investigators Should Converge with Pharmacometricians.
Maitland ML, O'Cearbhaill RE, Gobburu J. Maitland ML, et al. Clin Cancer Res. 2019 Sep 1;25(17):5182-5184. doi: 10.1158/1078-0432.CCR-19-1067. Epub 2019 Jun 27. Clin Cancer Res. 2019. PMID: 31248883 Free article.
Cancer pharmacogenomics: strategies and challenges.
Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Wheeler HE, et al. Among authors: maitland ml. Nat Rev Genet. 2013 Jan;14(1):23-34. doi: 10.1038/nrg3352. Epub 2012 Nov 27. Nat Rev Genet. 2013. PMID: 23183705 Free PMC article. Review.
Vascular endothelial growth factor pathway.
Maitland ML, Lou XJ, Ramirez J, Desai AA, Berlin DS, McLeod HL, Weichselbaum RR, Ratain MJ, Altman RB, Klein TE. Maitland ML, et al. Pharmacogenet Genomics. 2010 May;20(5):346-9. doi: 10.1097/FPC.0b013e3283364ed7. Pharmacogenet Genomics. 2010. PMID: 20124951 Free PMC article. Review. No abstract available.
Improving clinical trial design through quantitative pharmacology.
Maitland ML. Maitland ML. Clin Adv Hematol Oncol. 2016 Aug;14(8):606-8. Clin Adv Hematol Oncol. 2016. PMID: 27487104 No abstract available.
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D. Maitland ML, et al. Br J Cancer. 2018 Apr;118(8):1042-1050. doi: 10.1038/s41416-018-0020-2. Epub 2018 Mar 19. Br J Cancer. 2018. PMID: 29551775 Free PMC article. Clinical Trial.
Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.
Claret L, Pentafragka C, Karovic S, Zhao B, Schwartz LH, Maitland ML, Bruno R. Claret L, et al. Among authors: maitland ml. Cancer Chemother Pharmacol. 2018 Jul;82(1):49-54. doi: 10.1007/s00280-018-3587-7. Epub 2018 Apr 26. Cancer Chemother Pharmacol. 2018. PMID: 29700575 Clinical Trial.
Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.
Gupta R, Maitland ML. Gupta R, et al. Among authors: maitland ml. Curr Hypertens Rep. 2011 Dec;13(6):430-5. doi: 10.1007/s11906-011-0229-4. Curr Hypertens Rep. 2011. PMID: 21931979 Review.
Inflammation, growth factors, and pulmonary vascular remodeling.
Hassoun PM, Mouthon L, Barberà JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX, Humbert M. Hassoun PM, et al. Among authors: maitland ml. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S10-9. doi: 10.1016/j.jacc.2009.04.006. J Am Coll Cardiol. 2009. PMID: 19555853 Free article. Review.
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Maitland ML, Vasisht K, Ratain MJ. Maitland ML, et al. Trends Pharmacol Sci. 2006 Aug;27(8):432-7. doi: 10.1016/ Epub 2006 Jul 3. Trends Pharmacol Sci. 2006. PMID: 16815558 Review.
67 results
Jump to page